MDXG Stock Analysis: Buy, Sell, or Hold?
MDXG - MiMedx Group, Inc
$5.11
-0.03 (-0.58%)
▼
BUY
HIGH Confidence
Last Updated: January 30, 2026
Earnings: Feb 25, 2026
24d
Get Alerted When MDXG Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
4 traders called MDXG this week
17% bullish • 5 bearish
17% bullish • 5 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: MDXG shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: MDXG shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: MDXG is currently trading at $5.11, which is considered oversold relative to its 30-day fair value range of $5.45 to $6.75. From a valuation perspective, the stock is trading at a premium (Forward PE: 42.8) compared to its historical average (28.6). At these levels, the market is pricing in 14.4% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, MDXG is in a downtrend. The price is currently testing key support at $5.05. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $10.40 (+102.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MDXG is in a downtrend. The price is currently testing key support at $5.05. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $10.40 (+102.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$5.45 -
$6.75
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 102.3% below Wall St target ($10.40)
- NEUTRAL: PE elevated vs history but 14.4% growth expectation is conservative given 114% recent growth
Fair Price Analysis
30-Day Fair Range
$5.45 -
$6.75
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$5.05
Resistance Level
$5.72
Current Trend
Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
42.83
Wall Street Target
$10.40
(+102.3%)
Revenue Growth (YoY)
35.3%
Earnings Growth (YoY)
113.8%
Profit Margin
10.4%
Valuation Premium vs History
+14.4% premium
PE vs Historical
42.8 vs 28.6
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+14.4%
(market-implied from PE analysis)
1-Year Target
$5.88
(+14%)
2-Year Target
$6.73
(+31%)
3-Year Target
$7.70
(+50%)
3-Yr Target (if PE normalizes)
(PE: 43→29)
PE COMPRESSION
$5.14
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 42.8, Growth: -71.4%)
$3.75
(+-27%)
Base:
(SPY PE: 22.3, Growth: -71.4%)
$1.95
(-62%)
Bear:
(PE: 19.0, Growth: -71.4%)
$1.66
(-68%)
📈
Valuation based on Current Earnings
Trailing PE: 19.07 | Current EPS (TTM): $0.27
Bull Case
$2.83
(-45%)
Analyst growth -50.0%, PE expands to 21.0
Base Case
$2.58
(-50%)
Market implied -50.0%, PE stable at 19.1
Bear Case
$3.50
(-32%)
Severe decline -20.0%, PE contracts to 16.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Last updated: January 31, 2026 2:04 AM ET
Data refreshes hourly during market hours. Next update: 3:04 AM
Data refreshes hourly during market hours. Next update: 3:04 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MDXG showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$56 | 59 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$210 | 57 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$64 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$102 | 62 BUY |
|
ARVN
Arvinas Inc |
BUY
21 analysts |
$13 | 63 BUY |
Advanced MDXG Option Strategies
Professional options setups generated by AI based on today's MDXG price and gamma walls.
